Compare INTZ & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTZ | DARE |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 19.2M |
| IPO Year | 2020 | 2014 |
| Metric | INTZ | DARE |
|---|---|---|
| Price | $0.66 | $1.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.75 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 210.5K | 180.6K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,015,000.00 | $2,807,885.00 |
| Revenue This Year | $25.34 | $2,115.12 |
| Revenue Next Year | $14.70 | $122.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 21.56 | N/A |
| 52 Week Low | $0.66 | $1.13 |
| 52 Week High | $2.27 | $3.78 |
| Indicator | INTZ | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 46.07 |
| Support Level | $0.70 | $1.13 |
| Resistance Level | $0.88 | $1.88 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 12.67 | 97.78 |
Intrusion Inc is a cybersecurity company based in Plano, Texas. The company offers its customers access to its exclusive threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol addresses. Its platform combines threat intelligence, malicious traffic identification, and automated threat response, and is designed to help organizations proactively identify and stop malicious activity in their networks. Its solutions include INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. The company operates in single segment.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.